RxDoctor Payments DataLook up a doctor →

Gregg Eure, MD

Urology · Virginia Beach, VANPI 1316927163

Payments from drug & device makers

$1,531,585in general payments, 2019–2025

Across 1,671 payments — averaging $916.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1M
  • Neotract Inc.$352K
  • Calyxo, Inc.$71K
  • Boston Scientific$49K
  • Sumitomo Pharma America, Inc.$9K
  • Urovant Sciences Inc$6K
  • plus $25K from 37 others

What the payments were for

  • Consulting fees$330,38623%
  • Speaking & faculty fees$966,80467%
  • Grants$1250%
  • Travel & lodging$112,9238%
  • Food & beverage$38,8253%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,531,585 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$607,748
Medicare patients
977
Services billed
4,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron56$46,255
MyrbetriqMirabegron33$23,713
Trospium Chloride69$6,065
Finasteride446$5,744
Silodosin21$5,151
Tamsulosin Hcl354$4,697
Dutasteride86$2,600
Trimethoprim45$2,046
Oxybutynin Chloride ErOxybutynin Chloride37$945
NitrofurantoinNitrofurantoin Macrocrystal12$518
Alfuzosin Hcl ErAlfuzosin Hcl20$321
Cephalexin29$130
Ciprofloxacin Hcl11$57
Levofloxacin22$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$8,613$46,25556 claims
Astellas Pharma US IncMyrbetriq$430$23,71333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.

Other urology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →